Xenografting of human umbilical mesenchymal stem cells from Wharton’s jelly ameliorates mouse spinocerebellar ataxia type 1

  • Ming-Yuan Min (Creator)
  • Pei Jiun Tsai (Contributor)
  • Yu Show Fu (Contributor)
  • Wan-Jhen Huang (Creator)
  • Tzu Hao Huang (Creator)
  • Bing-Wen Soong (Veterans General Hospital-Taipei, National Yang Ming Chiao Tung University) (Creator)
  • Tsui Ling Ko (Contributor)
  • Chang Ching Yeh (Contributor)
  • Tien Hua Chen (Contributor)
  • Yu Pei Huang (Creator)
  • Sanford P.C. Hsu (Creator)



Abstract Background Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by the expansion of CAG repeats in ATXN1 gene resulting in an expansion of polyglutamine repeats in the ATXN1 protein. Unfortunately, there has yet been any effective treatment so far for SCA1. This study investigated the feasibility of transplanting human umbilical mesenchymal stem cells (HUMSCs) into transgenic SCA1 mice containing an expanded uninterrupted allele with 82 repeats in the ATXN1-coding region. Methods 106 human umbilical mesenchymal stem cells were transplanted into the cerebella at 1 month of age. Results HUMSCs displayed significant ameliorating effects in SCA1 mice in terms of motor behaviors in balance beam test and open field test as compared with the untransplanted SCA1 mice. HUMSCs transplantation effectively reduced the cerebellar atrophy, salvaged Purkinje cell death, and alleviated molecular layer shrinkage. Electrophysiological studies showed higher amplitudes of compound motor action potentials as indicated by increasing neuronal-muscular response strength to stimuli after stem cell transplantation. At 5 months after transplantation, HUMSCs scattering in the mice cerebella remained viable and secreted cytokines without differentiating into neuronal or glia cells. Conclusions Our findings provide hope for a new therapeutic direction for the treatment of SCA1.
Date made available2019

Cite this